Jaka jest cena za Molecular Pharmacology (USA), Ltd. (MLPH)

Cena za Molecular Pharmacology (USA), Ltd. (MLPH) wynosi $0.0322

Jaka jest kapitalizacja rynkowa dla Molecular Pharmacology (USA), Ltd. (MLPH)

Kapitalizacja rynkowa dla Molecular Pharmacology (USA), Ltd. (MLPH) wynosi $643.71K

Zyski Molecular Pharmacology (USA), Ltd. (MLPH)

As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is dedicated to the creation and market introduction of solutions for pain and inflammation, with a primary focus on the Australian and United States markets. Through its subsidiary, Molecular Pharmacology Pty. Ltd., it is advancing an analgesic and anti-inflammatory molecule called Tripeptofen, designed to alleviate common daily pain. These products are offered in diverse dosage forms, formulations, and packaging options to suit various needs. MLPH's marketing strategy involves leveraging pharmaceutical distributors and forging collaborative partnerships with companies in the United States and Europe. Additionally, the company maintains an agreement with Dermatology Development Corporation to jointly develop and market a suite of therapeutic, cosmetic, and cosmeceutical items derived from the ThermaLIFE product line and its core active component. Headquartered in Perth, Australia, Molecular Pharmacology (USA) Limited operates as a subsidiary of PharmaNet Group Limited.

Rok	Zyski	Zmień
Za mało danych dla podanych dat.

Rok

Zyski

Zmień

Za mało danych dla podanych dat.

Firma	Zyski	Różnica w zyskach	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$3.01B	-	BE

Firma

Zyski

Różnica w zyskach

Kraj